A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, Hirata Y, Sobue S, Mizushima T, Sano H, Mizuno Y, Nakamura M, Hirano A, Tsuchida K, Adachi K, Seno K, Kitagawa M, Kawai T, Joh T.
Kataoka H, et al. Among authors: kitagawa m.
Cancer Chemother Pharmacol. 2016 May;77(5):957-62. doi: 10.1007/s00280-016-3013-y. Epub 2016 Mar 22.
Cancer Chemother Pharmacol. 2016.
PMID: 27002325
Clinical Trial.